Disease-specific autoantibodies

Disease-specific autoantibodies are immunoglobulins produced by the immune system that mistakenly target and react with the body's own tissues, organs, or proteins (Ludwig et al., 2017). These molecules play a central role in the pathogenesis of numerous autoimmune disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and myasthenia gravis (MG), by inducing inflammation, cell lysis, or functional interference with receptors (Elkon & Casali, 2008). In many cases, the presence and titer of these autoantibodies correlate with disease activity and severity, making them critical diagnostic and prognostic biomarkers (Sherer et al., 2004). Therapeutic strategies targeting these autoantibodies focus on several mechanisms: depleting the B-cell populations that produce them (e.g., via CD20 targeting), physically removing them from circulation via plasmapheresis, or accelerating their degradation through the inhibition of the neonatal Fc receptor (FcRn) (Gable & Guptill, 2022). By reducing the concentration of pathogenic autoantibodies, these treatments aim to alleviate symptoms and prevent further tissue damage (Argov, 2022). However, broad depletion of antibodies can lead to significant safety concerns, primarily an increased risk of infections due to impaired humoral immunity (Hansel et al., 2010).

Other names

AutoantibodiesPathogenic autoantibodiesSelf-reactive antibodiesNatural autoantibodies

Therapeutic strategies include the depletion of B-lymphocytes to prevent autoantibody production, the use of neonatal Fc receptor (FcRn) antagonists to accelerate the clearance of pathogenic IgG, and the physical removal of antibodies via plasmapheresis or immunoadsorption.